1st Department of Internal Medicine, Semmelweis University, Budapest, 2/A Koranyi S U, Budapest, Hungary.
Int Urol Nephrol. 2010 Sep;42(3):723-39. doi: 10.1007/s11255-009-9666-2. Epub 2009 Dec 29.
Disorders of bone and mineral metabolism affect almost all patients with advanced chronic kidney disease (CKD). High prevalence of decreased bone mineral density has been reported in this population; however, the role and diagnostic utility of bone density measurements are not well established. The incidence of bone fractures is high in patients with ESRD, but the association between fractures and bone density is not obvious. A recent meta-analysis suggested that decreased density at the radius might be associated with higher overall fracture risk. Changes in bone mineral density reflect several underlying pathological processes, such as vitamin D deficiency, estrogen deficiency and changes in bone turnover. The response of bone to these factors and processes is not uniform: it can vary in different compartments of the same bone or in different bones of the skeleton. Therefore, it is important to differentiate between the various types of bone. This may be possible by proper selection of the measurement site or using methods such as quantitative bone computed tomography. Previous studies used different methods and measured bone mineral density at diverse sites of the skeleton, which makes the comparison of their results very difficult. The association between changes in bone mineral metabolism and cardiovascular mortality is well known in ESRD patients. Studies also suggest that low bone density itself might be an indicator for high risk of cardiovascular events and poor overall outcome in this population. Some of the risk factors of low bone mineral density, such as vitamin D or estrogen deficiency, are potentially modifiable. Further studies are needed to elucidate if interventions modifying these risk factors will have an impact on clinical outcomes. In this review, we discuss the options for and problems of assessment of bone density and summarize the literature about factors associated with low bone density and its link to clinical outcomes in patients on maintenance dialysis.
骨骼和矿物质代谢紊乱几乎影响所有晚期慢性肾脏病(CKD)患者。该人群中已报道骨密度降低的高患病率;然而,骨密度测量的作用和诊断效用尚未得到很好的确定。ESRD 患者骨折的发生率很高,但骨折与骨密度之间的关联并不明显。最近的一项荟萃分析表明,桡骨密度降低可能与更高的总体骨折风险相关。骨矿物质密度的变化反映了几种潜在的病理过程,如维生素 D 缺乏、雌激素缺乏和骨转换变化。骨骼对这些因素和过程的反应并不一致:它可以在同一骨骼的不同部位或骨骼的不同骨骼中发生变化。因此,区分不同类型的骨骼很重要。这可以通过适当选择测量部位或使用定量骨计算机断层扫描等方法来实现。以前的研究使用了不同的方法,并在骨骼的不同部位测量了骨矿物质密度,这使得比较它们的结果非常困难。骨矿物质代谢变化与 ESRD 患者心血管死亡率之间的关联是众所周知的。研究还表明,低骨密度本身可能是该人群心血管事件风险高和整体预后不良的一个指标。一些低骨矿物质密度的危险因素,如维生素 D 或雌激素缺乏,是潜在可改变的。需要进一步的研究来阐明是否改变这些危险因素的干预措施将对临床结果产生影响。在这篇综述中,我们讨论了评估骨密度的选择和问题,并总结了关于维持性透析患者中与低骨密度相关的因素及其与临床结果之间的联系的文献。